Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 6641 - 6648 of 12008 results

ML Strategies Explores the Evolution of “Repeal and Replace”
September 28, 2017| Blog| Viewpoint

Lawmakers May Not Spend Political Capital on Stand-Alone EB-5 Bill
September 28, 2017| Alert| Viewpoint

What Does the EEOC’s Lawsuit Against Estee Lauder Mean for Parental Leave Policies?
September 27, 2017| Blog| Viewpoint

New Qui Tam Update from Mintz’s Health Care Enforcement Defense Group
September 27, 2017| Blog| Viewpoint

Making the Sausage: Lower Courts Grapple With the Supreme Court’s TC Heartland Venue Decision
September 27, 2017| Blog| Viewpoint

“In Light of the Specification”: Federal Circuit Weighs in on the Broadest Reasonable Interpretation
September 27, 2017| Blog| Viewpoint

Building a Health App? Part Two: Protecting Your Intellectual Property
September 26, 2017| Blog| Viewpoint

Latest Travel Restrictions from Trump Administration
September 26, 2017| Alert| Viewpoint
News & Press Releases
Mintz advised The Eagle Leasing Company, a leading provider of portable storage containers, ground level offices, semi-trailers, and mobile office solutions, in its acquisition by Rent-A-Container (RAC), a portfolio company of Kinderhook Industries, LLC.
Mintz’s Life Sciences practice has been shortlisted in multiple categories for the 2025 LMG Life Sciences Americas Awards. The winners will be announced at an awards ceremony in New York on September 4. In the United States, Mintz was shortlisted in the “Venture Capital Firm of the Year” category. In Canada, Mintz was shortlisted in the “Financial & Corporate Firm of the Year” and “Patent Strategy Firm of the Year” categories.
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
